The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients

References

• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
   PubMed Web of Science ®Google Scholar
• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–1933.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol. 2011;23(2):214–220.
   PubMed Web of Science ®Google Scholar
• Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019;54(4):508–518.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33(32):3741–3749.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am. 2014;28(6):1131–1144.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Roussou M, Gavriatopoulou M, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60–65.
   PubMed Web of Science ®Google Scholar
• Huang X, Wang Q, Chen W, et al. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement. Amyloid. 2016;23(1):51–57.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Kumar SK, Gertz MA, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91(10):984–988.
   PubMed Web of Science ®Google Scholar
• Afrough A, Saliba RM, Hamdi A, et al. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(11):2197–2203.
   PubMed Web of Science ®Google Scholar
• Huang X, Wang Q, Chen W, et al. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014;12:2
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Cin Oncol. 2013;31(34):4319–4324.
   PubMed Web of Science ®Google Scholar
• Tovar N, Rodriguez-Lobato LG, Cibeira MT, et al. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid. 2018;25(2):79–85.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kourelis TV, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020;34(4):1135–1143.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90(8):1054–1081.
   PubMed Web of Science ®Google Scholar
• Dittus C, Uwumugambi N, Sun F, et al. The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1729–1732.
   PubMed Web of Science ®Google Scholar
• Huang X, Fu C, Chen L, et al. Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis. Am J Hematol. 2019;94(4):E101–E104.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am. J. Hematol. 2005;79(4):319–328.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Cin Oncol. 2004;22(18):3751–3757.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Cin Oncol. 2012;30(9):989–995.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Milani P, Basset M, Russo F, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–631.
   PubMed Web of Science ®Google Scholar
• Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632–642.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Cin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33(4):381–388.
   PubMed Web of Science ®Google Scholar
• Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127(5):543–551.
   PubMed Web of Science ®Google Scholar
• Landau H, Smith M, Landry C, et al. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2017;31(1):136–142.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: Results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21(8):1445–1451.
   PubMed Web of Science ®Google Scholar
• Scott EC, Heitner SB, Dibb W, et al. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leuk. 2014;14(5):424–430. e421.
   PubMed Web of Science ®Google Scholar
• Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27(4):823–828.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016;99:249–260.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842–848.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Cin Oncol. 2001;19(14):3350–3356.
   PubMed Web of Science ®Google Scholar
• Minnema MC, Nasserinejad K, Hazenberg B, et al. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 2019;104(11):2274–2282.
   PubMed Web of Science ®Google Scholar
• Mikhael J. Turn off the tap! The need for induction therapy for al amyloidosis before transplantation. Biol Blood Marrow Transplant. 2018;24(11):e1–e2.
   PubMedGoogle Scholar